Exploring the Progress and Evolving Therapeutic Paradigm in Multiple Myeloma

Gain insights on the evolving treatment paradigm in multiple myeloma with an on-demand webcast, downloadable slideset, and expert commentary.

Share

Program Content

Activities

Multiple Myeloma Update
An Update in Diagnosis, Prognosis, and Treatment of Multiple Myeloma – for the Treating Oncologist
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2023

Immuno-Oncology Multiple Myeloma
Immuno-Oncology in Myeloma: New Indications and Approvals
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2023

New Opportunities: Myeloma
New Therapeutic Opportunities in Myeloma
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2023

Activities

Evolving Paradigm in Multiple Myeloma
Exploring the Progress and Evolving Therapeutic Paradigm in Multiple Myeloma
Video
Congratulations: You achieved a completion on 04/09/2022

Released: June 21, 2023

Expires: June 20, 2024

Activities

FAQs on BCMA SLAMF7 in MM
Experts Answer Questions About Therapies Targeting BCMA and SLAMF7 in Multiple Myeloma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 20, 2023

Faculty

cover img faculity

Joseph Mikhael, MD, MEd, FRCPC, FACP

Professor
Applied Cancer Research and Drug Discovery 
Translational Genomics Research Institute 
Phoenix, Arizona
Chief Medical Officer
International Myeloma Foundation 
HonorHealth Research Institute 
Scottsdale, Arizona

cover img faculity

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

cover img faculity

Noopur Raje, MD

Director
Center for Multiple Myeloma
Rita Kelly Chair in Oncology
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AbbVie Inc., Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Karyopharm Therapeutics, Legend Biotech USA Inc., and Pfizer Inc.

AbbVie Inc.

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics Inc.

Legend Biotech USA Inc.

Pfizer, Inc.